Introduction
The need for rapid antibiotic susceptibility testing (AST) increases with escalating levels of antimicrobial resistance in Enterobacteriaceae. In seriously ill patients the time elapsed to correct antimicrobial treatment is of vital importance for survival. 1 Timely and reliable susceptibility reports from the laboratory also facilitate antibiotic stewardship programmes to enable change from broad-spectrum antibiotic treatment, such as with carbapenems, to targeted narrow-spectrum antibiotic treatment. 2 Limiting the use of carbapenems is important to avoid further selection of resistance. 3 Phenotypic susceptibility testing is necessary for Enterobacteriaceae since there are many different mechanisms of resistance, which makes genotype-based approaches challenging. 4 In addition, PCR-based approaches are able to identify only resistance, not susceptibility. There are many ongoing efforts to find new ways to shorten the time from positive blood culture to AST results, including, microfluidic platforms, digital time-lapse cytometry, two-photon excitation fluorometry, automated digital microscopy and MS-based approaches. [5] [6] [7] [8] [9] [10] Some of these new methods are promising, but they have in common that they are still expensive, labour intensive and commonly suitable only for single-sample tests and a limited number of antimicrobials.
EUCAST disc diffusion is a routine method of AST in many laboratories and is a well-established, cost-effective, reliable method for AST. The main drawback of disc diffusion is that it requires overnight (16-20 h ) incubation, according to guidelines. tion for Enterobacteriaceae, but information on the accuracy of reading inhibition zones after only 6 h of incubation is limited. 12, 13 For laboratories using disc diffusion, there is a great potential to shorten the time before susceptibility results become available by up to 10-14 h, with little extra cost, if early reading of zones is shown to be accurate.
Herein, we used digital imaging with a total laboratory automation system (BD Kiestra TM ) to study the development of inhibition zones over time. We evaluated the performance of application of EUCAST breakpoints on inhibition zones read after 6 h of incubation on a large collection of Escherichia coli and Klebsiella pneumoniae with diverse resistance mechanisms. Figure S1 . The numbers refer to the number of observations for each data point. There were 153 observations on 128 isolates for all antibiotics, except for amikacin, which had 152 observations on 127 isolates. EUCAST breakpoints applied to both readings are shown as lines (solid line, R/I breakpoint; dashed line, S/I breakpoint). For meropenem the dotted lines show the CPE screening breakpoint. Results within the grey shaded areas are classified as uncertain according to the tentative breakpoints for the 6 h reading.
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Materials and methods
Specimen collection
A total of 128 isolates were included in the study, of the species E. coli (n ¼ 68) and K. pneumoniae (n ¼ 60). The selected isolates represented a wide variety of resistance mechanisms, including carbapenemase-producing Enterobacteriaceae (CPE, n ¼ 43), ESBL producers (n ¼ 42) and non-ESBL/CPE producers (n ¼ 43) (Table S1 , available as Supplementary data at JAC Online). The ESBL and non-ESBL isolates were clinical isolates from bloodstream infections, retrieved from blood cultures analysed at the Karolinska University Laboratory, Stockholm, in 2013-14. The carbapenemase-producing isolates were well-characterized, derived from both clinical infections and faecal screening, and had been found to produce KPC (n ¼ 14), NDM-1 (n ¼ 13), VIM (n ¼ 2) and OXA-48 (n ¼ 14). The CPE isolates have been characterized with Check-MDR at the Karolinska University Laboratory.
14 Antimicrobial agents and phenotypic detection of ESBL and carbapenemase
AST was performed on all isolates from overnight culture according to EUCAST disc diffusion methodology, 11 using Mueller-Hinton (MH) agar and antibiotic discs from Oxoid/Thermo Fisher Scientific (Basingstoke, UK). In addition to AST, we evaluated rapid reading of phenotypic tests for production of ESBL and carbapenemase production with tablet kits from For rapid ESBL detection, we evaluated early reading of the ESBL Confirm kit 98011 from ROSCO Diagnostica A/S. This kit consists of four tablets: cefotaxime 30 lg 6 clavulanate and ceftazidime 30 lg 6 clavulanate. A difference of !5 mm between the inhibition zone with and without clavulanate for either cefotaxime or ceftazidime was interpreted as positive for ESBL, if the isolate was cefoxitin susceptible. A difference of <5 mm in cefoxitin-susceptible isolates was interpreted as negative. Cefoxitin resistance is indicative of the presence of AmpC b-lactamases, which can mask the presence of ESBL when using phenotypic tests with clavulanate. Cefoxitin-resistant isolates were thus classified as inconclusive, since these isolates would need further investigation with additional tests. 15 Evaluated phenotypic carbapenemase tests included the KPC/MBL and OXA-48 Confirm kit 98015 from ROSCO Diagnostica A/S (consisting of meropenem 10 lg, meropenem 10 lg þ phenylboronic acid, meropenem 10 lg þ cloxacillin, meropenem 10 lg þ dipicolinic acid and temocillin 30 lg) and the Carbapenamase Activity Test (CAT-ID) disc from Mast Group Ltd., containing faropenem. The two tests were performed according to the manufacturers' instructions with an inoculum with a turbidity equivalent to that of a 0.5 McFarland standard, incubated for 16-20 h and then interpreted. Interpretation of the ROSCO CPE kit result was as follows: MBL suspicion, synergy with dipicolinic acid; KPC suspicion, synergy with phenylboronic acid, but not cloxacillin; OXA-48 suspicion, no synergy, temocillin <12 mm; and negative, no synergy and temocillin !12 mm, or synergy with cloxacillin and boronic acid or only cloxacillin. Interpretation of the CAT-ID test was as follows: MBL/KPC suspicion, no inhibition zone; OXA-48 suspicion, double zone with microcolonies; and negative, clear zone.
Rapid AST-early reading of inhibition zones
AST was performed according to EUCAST and phenotypic tests according to the manufacturer. Prepared MH plates were entered into the BD Kiestra TM Total Lab Automation System, which produced digital photographic images of each plate after 6 and 18 h of incubation. Inhibition zone diameters obtained by manual reading of zones on the digital images using the Kiestra ReadA software at the different incubation times were compared with manual readings with a calliper of the same MH plates at 16-20 h. AST was performed in duplicate on a subset of 25 isolates.
EUCAST breakpoints were applied to all AST readings. 16 The correlation between rapid AST and EUCAST methodology was categorized as: very major error (VME) [i.e. rapid AST ¼ susceptible (S), EUCAST ¼ resistant (R)]; major error (ME) (i.e. rapid AST ¼ R, EUCAST ¼ S); or minor error (mE), including all errors with an intermediate (I) result in any of the two tests. Categorical agreement represented the same S/I/R result with the two tests. Essential agreement was defined as 6 3 mm difference between the two readings. 17 
Results
Antimicrobial susceptibility testing at 6 h Inhibition zones were readable at 6 h with only a few exceptions. For susceptible isolates, inhibition zones were smaller at 6 h compared with 18 h (mean difference 2.7 mm, SD 61.9 mm), while resistant isolates were more unpredictable: sometimes they had larger inhibition zone sizes at 6 h compared with 18 h and sometimes smaller (mean difference À1.1 mm, SD 62.7 mm).
Application of EUCAST breakpoints on the early readings yielded the results shown in Table 1 . The correlation between rapid AST and EUCAST methodology for cefotaxime, ceftazidime, piperacillin/tazobactam, meropenem, ertapenem, ciprofloxacin, gentamicin and amikacin is presented in Figure 1(a-h) . For other antibiotics, see Figure S1 . Categorical agreement varied between 82% for imipenem and 99% for cefotaxime. There were neither MEs nor VMEs for cefotaxime, ciprofloxacin or amikacin. The carbapenems and trimethoprim/sulfamethoxazole had a relatively high rate of VMEs: meropenem 0.7%, imipenem 1.3% and trimethoprim/sulfamethoxazole 3.9%. For these antibiotics completely clear inhibition zones were commonly seen at 6 h, but at 18 h Rapid disc diffusion of E. coli and K. pneumoniae JAC there was obvious growth within the zones. Ciprofloxacin had a high rate of mEs at 11.7%, which was most often due to smaller inhibition zones at 6 h than at 18 h, causing susceptible isolates to be reported as intermediate.
Application of tentative breakpoints for 6 h reading
At the Twenty-sixth European Congress of Clinical Microbiology and Infectious Diseases in 2016, Jonasson et al. 18 presented tentative breakpoints for 6 h readings of disc diffusion. With these breakpoints, a new category was introduced, 'uncertain', which is applied for inhibition zones that fall in an interval of technical uncertainty. The results of our study support the need for a buffer zone for 6 h readings, to avoid MEs or VMEs. However, if too many isolates have zones falling into this category, the 6 h reading is of limited benefit.
We applied the suggested tentative breakpoints to the measurements in the present study (Table 2) . With the tentative breakpoints, almost all errors were eliminated; only an mE of 0.7% (one isolate) for meropenem remained. The rate of measurements that fell in the uncertain category was 4% for cefotaxime, 10% for ceftazidime, 33% for piperacillin/tazobactam, 20% for meropenem, 15% for ciprofloxacin and 20% for gentamicin. For ESBL-producing isolates, the rate of uncertain results was considerably higher for most antibiotics, and as many as 68% of the ESBL-producing isolates were uncertain for piperacillin/tazobactam. For the CPE isolates, there were no uncertain results for piperacillin/tazobactam, but all of these isolates were clearly resistant.
Phenotypic detection of ESBL
At 6 h of incubation, 88 isolates were interpreted as intermediate or resistant to cefotaxime or ceftazidime, and were relevant to the assessment of ESBL production. For these isolates, the 6 h reading of the ROSCO Diagnostica Confirm kit 98011 was evaluated (Table 3) . At 6 h, 39 isolates were correctly identified as ESBL producers, which gave an overall sensitivity for detection of ESBL production of 87% in this collection. The rest of the isolates were interpreted as inconclusive as they were cefoxitin resistant.
The 6 h performance of the ESBL test was most influenced by the cefoxitin zone reading. In 5 out of the 45 isolates (11%), which were ESBL positive and cefoxitin susceptible at 18 h, the cefoxitin zone increased in size, changing from resistant at 6 h to susceptible at 18 h. This caused the interpretation of the ESBL test to change from inconclusive at 6 h to positive at 18 h. A total of 81 isolates were interpreted as cefoxitin susceptible at 6 h. Thirty-nine of these isolates were cephalosporin-resistant ESBL producers. For these 81 isolates, the sensitivity of the ESBL test read at 6 h was 98% and the specificity 100%.
For the KPC-and NDM-producing isolates, the reading of ESBL zones was difficult, as they often had inhibition zones close to the cut-off at !5 mm difference, and results varied between 6 and 18 h. However, all except one of these isolates were cefoxitin resistant and therefore judged to be inconclusive, as the presence of other b-lactamases will mask clavulanic acid synergy.
Detection of CPE
Carbapenemase production should be suspected in Enterobacteriaceae with an inhibition zone of <27 mm for meropenem Fröding et al.
10 lg with the standard EUCAST procedure. 15 Since WT isolates have smaller inhibition zones for meropenem at 6 h (Figure 1d ), the specificity of the meropenem screening breakpoint is lower. We performed a receiver operating characteristic (ROC) analysis for the inhibition zone size of meropenem 10 lg discs for the detection of CPE at 6 h of incubation. A breakpoint of <26 mm at 6 h maintained a sensitivity of 100%, with a specificity of 85% in this collection, while a breakpoint of <27 mm gave a sensitivity of 100%, but the specificity was reduced to 67%. At 18 h the breakpoint of <27 mm had a sensitivity of 100% and a specificity of 98%. In this collection, there were no CPEs with a meropenem inhibition zone of 25-26 mm, which some OXA-48 producers can have, and which is the rationale for the <27 mm breakpoint. A ROC analysis was also performed for ertapenem, but the result was not much better than for meropenem (breakpoint at 6 h <25 mm, sensitivity 100%, specificity 85%; breakpoint at 18 h <24 mm, sensitivity 100%, specificity 97%).
Faropenem (used at 10 lg in the CAT-ID assay, Mast Group Ltd.) is a penem that has previously been used for CPE screening. 19 According to the manufacturer of the CAT-ID assay, no zone of Only results from isolates with meropenem inhibition zone <27 mm at 6 h are shown (n ¼ 74).
a For the Mast CAT-ID test one of the OXA-48 isolates had a negative result (clear zone) at 18 h and for the ROSCO test two OXA-48 isolates were negative (temocillin !12 mm) at 18 h of incubation and were therefore classified as negative at 18 h. When repeated, the temocillin zones at 18 h were just below 12 mm for these two isolates. For calculation of sensitivity and specificity the inconclusive tests were regarded as negative.
Rapid disc diffusion of E. coli and K. pneumoniae JAC inhibition is indicative of KPC or MBL carbapenemases. The test discriminates between OXA-48 and negative results by the presence of colonies growing within the zone, called a 'double zone', a clear zone with microcolonies growing within the zone. In this study, 127 isolates were tested with the CAT-ID (143 observations, as 16 isolates were tested in duplicate). At 18 h of incubation all KPC and MBL isolates were correctly identified with no inhibition zone. Detection of OXA-48 was more difficult, and only 13 out of 14 OXA-48 producers were correctly identified. The overall performance of the CAT-ID test at 18 h (all 127 tested isolates) was, for MBL detection (i.e. no zone), a sensitivity of 100% and a specificity of 98%, and, for OXA-48 (i.e. colonies in zone), a sensitivity of 81% and a specificity of 100%. Although the manufacturer does not recommend measuring inhibition zone sizes for faropenem, we performed a ROC analysis for the 18 h faropenem inhibition zone sizes (inner zone measured) to see whether it was possible to find a useful breakpoint for carbapenemase screening. At 18 h, a faropenem breakpoint of <18 mm would have a sensitivity of 100% and a specificity of 97%, which is comparable to meropenem. At 6 h, 74 isolates with meropenem 10 lg zones <27 mm were suspected of being CPE, and included in the detailed analysis for the two evaluated carbapenemase tests (Table 4 and Table S2 ). At 6 h the sensitivity of faropenem for detection of OXA-48 was 0% (microcolonies were not visible at this time), while the sensitivity for detection of KPC/MBL was 97%. The specificity for correct CPE was 98% for KPC/MBL.
We also evaluated 6 h reading of the KPC/MBL and OXA-48 Confirm kit 98015 from ROSCO Diagnostica A/S. Of the 43 CPE isolates tested, only 41 were positive at 18 h. Two OXA-48 isolates were not identified at the 18 h reading, due to temocillin zones !12 mm. However, when repeated, the temocillin zones were just below 12 mm for these borderline temocillin-resistant OXA-48 isolates. These two isolates were classified as negative in the evaluation of the 6 h reading (Table 4 and Table S2 ). For the 74 isolates with meropenem zones <27 mm, the sensitivity (for correct CPE) of the ROSCO Diagnostica test at 6 h was 71% for OXA-48, 93% for KPC and 83% for MBL. The specificity at 6 h was 97% for OXA-48 and 100% for KPC and MBL. The overall sensitivity of the 6 h reading for CPE was 85%, but 5% were misidentified. The specificity of any positive result (disregarding the misidentifications) was 100%.
Discussion
Disc diffusion inhibition zones are in most cases visible at 6 h for rapidly growing microorganisms such as Enterobacteriaceae. It is clear that the margin between the inhibition zones of resistant and susceptible isolates is much smaller at 6 h than at 18 h, which is a source of error. Some antibiotics, such as cefotaxime, seem to stabilize the inhibition zone size at an earlier time, and have acceptable separation between susceptible and resistant isolates at 6 h. In settings where cefotaxime is used for empirical therapy of bloodstream infections and disc diffusion is the routine AST method, this early reading of inhibition zones could have great clinical impact, although this remains to be shown in prospective trials. Other antibiotics have a much larger grey zone at 6 h, where the same zone can become either susceptible or resistant at 18 h of incubation.
The results herein support the use of adapted breakpoints for the 6 h reading, as suggested by Jonasson et al. 18 to address the problem of the large number of mEs and MEs occurring for isolates with inhibition zones in this grey zone, close to the normal breakpoints. Application of the tentative 6 h breakpoints to our collection eliminated all errors except for one CPE isolate regarding meropenem (Table 2) . However, one-third of all isolates and as many as two-thirds of the ESBL isolates were classified as uncertain for piperacillin/tazobactam at 6 h, which clearly limits the use of the 6 h reading for this antimicrobial. Interestingly, only 2% of the ESBL-producing isolates were uncertain for cefotaxime. Not all ESBL isolates in this study have been molecularly investigated. However, they were consecutive isolates from bloodstream infections in Stockholm, Sweden, where CTX-M is the most common enzyme, and most of these isolates are more resistant to cefotaxime than to ceftazidime. The results would likely be different in a collection that included more isolates with a ceftazidimase profile, where the performance of cefotaxime would probably be somewhat poorer. The relatively clear-cut resistance for cefotaxime and ceftazidime also reflects the situation in clinical practice, as enzymatic cephalosporin resistance is usually much easier to detect than carbapenem resistance.
Our results indicate that it should be possible to define 6 h breakpoints also for amikacin. For trimethoprim/sulfamethoxazole only clearly resistant results at 6 h should be trusted, while all isolates with susceptible results at 6 h would be needed to be called uncertain, in order to avoid VMEs.
ESBL detection
The 6 h performance of the ESBL test was mostly influenced by the cefoxitin zone reading, as several isolates went from inconclusive at 6 h to positive at 18 h. The detection of ESBL can be masked by AmpC b-lactamases, which is why cefoxitin-resistant isolates are designated inconclusive, but the interpretation of ESBL tests with clavulanate synergy tests are also difficult in isolates producing KPC and MBL carbapenemases. 15 Unfortunately, the possible presence of these would not always be known at 6 h. A positive or negative ESBL result at 6 h would thus be needed to be confirmed if further susceptibility testing were to show the presence of carbapenemase or cefoxitin resistance.
A limitation of this study is that the collection did not include any cefotaxime-resistant isolates that were completely negative in the ESBL test, but not cefoxitin resistant, so the presence of potentially false positive results at 6 h in this unusual phenotype has not been evaluated.
CPE detection
Early detection of carbapenemase production is difficult, since heteroresistant subpopulations require 16-20 h of incubation to become visible, and the WT isolates have considerably smaller inhibition zones sizes at early readings. Although the EUCAST meropenem screening breakpoint of <27 mm has 100% sensitivity at 6 h of incubation, the specificity of only 67% makes this test unhelpful. However, highly resistant isolates (mainly KPC and MBL) can often be suspected at early readings for both meropenem and CAT-ID if no zone of inhibition is seen at all. Detection of OXA-48 isolates is, however, not reliable at the 6 h reading with any of the Fröding et al.
methods evaluated in this study. The results of this study also highlight the well-known challenge for laboratories of detecting OXA-48, 20, 21 since both tests failed to identify certain isolates of OXA-48 even after 18 h of incubation.
Conclusions
We conclude that inhibition zone reading at 6 h is an accurate method for susceptibility testing of extended-spectrum cephalosporins for Enterobacteriaceae. The tentative breakpoints applied to 6 h readings are useful and give accurate susceptibility categorization. More than 80% of the isolates in this study could be correctly interpreted at 6 h for cefotaxime, ceftazidime, meropenem, ciprofloxacin and gentamicin. The area of uncertainty category 18 provides a valuable safety margin for the borderline isolates. However, for piperacillin/tazobactam, the usefulness of the 6 h reading is limited, especially in settings of high ESBL prevalence, since a majority of ESBL-producing isolates fall into the uncertain category. The ROSCO Diagnostica ESBL Confirm kit 98011 test can be read at 6 h in isolates lacking cefoxitin resistance, but is not reliable in isolates with cefoxitin resistance. For accurate detection of all types of carbapenemase-producing isolates, the full 16-20 h of incubation is necessary for all evaluated methods: meropenem 10 lg, CAT-ID and ROSCO KPC/MBL and OXA-48 Confirm kit.
